

52968. The time, place, and public comment period of the ACD, CDC—HDS meeting has changed. The meeting will also be teleconferenced.

Time: 2 p.m.–3:30 p.m.

Place: CDC, 1600 Clifton Road, NE., Atlanta, GA 30333, Building 19, Room 247/248, Global Communication Center. To participate by teleconference, please dial 1–800–369–2112 and enter passcode 4102105.

Status: Open to the public; teleconference access limited only by availability of telephone ports. The public is welcome to participate during the public comments period which is tentatively scheduled from 3 to 3:15 p.m. EDT.

Contact Person for More Information: Walter W. Williams, M.D., M.P.H., Designated Federal Officer, ACD, CDC—HDS, 1600 Clifton Road, NE., M/S E67, Atlanta, Georgia 30333. Telephone 404–498–2310, E-mail: www1@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: October 22, 2009.

Elaine Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9–26054 Filed 10–27–09; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel; Conference Grant Review With An Environmental Health Focus.

Date: November 20, 2009.

Time: 1 p.m. to 3:30 p.m.

Agenda: To review and evaluate grant applications.

Place: Nat'l Institute of Environmental Health Sciences, 530 Davis Drive, Morrisville, NC 27560 (Telephone Conference Call).

Contact Person: Teresa Nesbitt, PhD, DVM, Chief, Scientific Review Branch, Division of Extramural Research and Training, Nat'l Institute of Environmental Health Sciences, P.O. Box 12233, MD EC–30, Research Triangle Park, NC 27709, (919) 541–7571, nesbitt@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS)

Dated: October 22, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9–25995 Filed 10–27–09; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Centers for Disease Control and Prevention

Healthcare Infection Control Practices Advisory Committee, (HICPAC)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned committee:

Times and Dates: 9 a.m.–5 p.m., November 12, 2009. 9 a.m.–12 p.m., November 13, 2009.

Place: Washington Marriott at Metro Center, Salons C–D, 775 12th Street, NW., Washington, DC 20005, Telephone: (202) 737–2200.

Status: Open to the public, limited only by the space available.

Purpose: The Committee is charged with providing advice and guidance to the Secretary, HHS; the Assistant Secretary for Health, HHS; the Director, CDC; and the Director, National Center for Preparedness, Detection, and Control of Infectious Diseases (NCPDCID), regarding: (1) The practice of hospital infection control; (2) strategies for surveillance, prevention, and control of infections (e.g., nosocomial infections), antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of guidelines and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions.

Matters To Be Discussed: The agenda will include updates on Recovery Act activities and the draft guideline for prevention of intravascular catheter-related bloodstream infections, and discussion of infection control in ambulatory care settings.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information:

Michelle King, HICPAC, Division of Healthcare Quality Promotion, NCPDCID, CDC, 1600 Clifton Road, NE., Mailstop A–07, Atlanta, Georgia 30333 Telephone (404) 639–2936.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: October 20, 2009.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9–25913 Filed 10–27–09; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Systems for Biomarker Research and Development.

Date: November 23, 2009.

Time: 11 a.m. to 1 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, 6116 Executive Boulevard, Suite 703, Room 7142, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Thomas M. Vollberg, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 7142, Bethesda, MD 20892, 301–594–9582, vollbert@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: October 22, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-25909 Filed 10-27-09; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of Biotechnology Activities; Recombinant DNA Research: Proposed Actions Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)

ACTION: Notice of consideration of a proposed action under the *NIH Guidelines*.

SUMMARY: A proposal by Dr. Harlan Caldwell at the Rocky Mountain Laboratories (RML) involving the deliberate transfer of a tetracycline resistance trait to non-ocular strains of *Chlamydia trachomatis* has been submitted to the NIH Office of Biotechnology Activities (OBA). The introduction of tetracycline resistance could compromise the ability to treat disease caused by *Chlamydia trachomatis* as doxycycline is currently used to treat disease caused by this organism. Under Section III-A-1 of the *NIH Guidelines*, if the deliberate transfer of a drug resistance trait to microorganisms could compromise the use of the drug to control disease in humans, veterinary medicine, or agriculture the experiment must be reviewed by the NIH Recombinant DNA Advisory Committee (RAC) and approved by the NIH Director.

On September 24, 2007 the NIH Director granted approval to Dr. Daniel Rockey, Oregon State University and Dr. Walter Stamm, University of Washington, to introduce tetracycline resistance into non-ocular strains of *Chlamydia trachomatis* under the containment level recommended by the RAC—Biosafety level 2 containment with Biosafety level 3 practices (see *NIH Guidelines* Appendix G-II-B and G-II-C). The requirements regarding containment as well as additional

required occupational health measures were published in the **Federal Register** (72 FR 61661). This approval was specific for Dr. Rockey at Oregon State University and Dr. Stamm at the University of Washington.

Dr. Caldwell at RML is proposing to develop a plasmid-based system to define the experimental conditions required for transformation of non-ocular *C. trachomatis* strains to tetracycline resistance. The investigators are proposing to perform these experiments under the same containment and implement the same occupational health measures required for the research proposed by Drs. Rockey and Stamm (72 FR 61661). This proposal will be discussed at the December 1–3, 2009 meeting of NIH Recombinant DNA Advisory Committee.

DATES: The public is encouraged to submit written comments on this proposed action. Comments may be submitted to the OBA in paper or electronic form at the OBA mailing, fax, and e-mail addresses shown below under the heading **FOR FURTHER INFORMATION CONTACT**. The NIH will consider all comments submitted by November 25, 2009. Written comments submitted by November 12, 2009 will be reproduced and distributed to the RAC for consideration at its December 1–3, 2009 meeting. In addition, an opportunity for public comment will be provided at that meeting. All written comments received in response to this notice will be available for public inspection at the NIH OBA office, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892 (telephone, 301-496-9838), weekdays between the hours of 8:30 a.m. and 5 p.m.

FOR FURTHER INFORMATION CONTACT:

Contact OBA by e-mail at oba@od.nih.gov, or telephone at 301-496-9838, if you have questions, or require additional information about this proposed action. Comments may be submitted to the same email address or by fax at 301-496-9839 or sent by U.S. mail to the Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, Maryland 20892-7985. For additional information about the RAC meeting at which this proposed action will be deliberated, please visit the NIH OBA Web site at: <http://oba.od.nih.gov/oba/index.html>.

SUPPLEMENTARY INFORMATION:

Background information may be obtained by contacting NIH OBA via e-mail at oba@od.nih.gov or by going to the OBA Web site at http://oba.od.nih.gov/rdna_rac/rac_meetings.html.

Dated: October 21, 2009.

Jacqueline Corrigan-Curay,

Acting Director, Office of Biotechnology Activities, National Institutes of Health.

[FR Doc. E9-25925 Filed 10-27-09; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

Office of the Secretary

Privacy Act of 1974; Consolidation of Department of Homeland Security Office of Inspector General System of Records

AGENCY: Privacy Office, DHS.

ACTION: Notice to consolidate one Privacy Act system of records notice.

SUMMARY: In accordance with the Privacy Act of 1974 the Department of Homeland Security is giving notice that it proposes to consolidate the Privacy Act system of records notice titled, Department of Homeland Security Office of Inspector—001 General Audit Training Tracking System of Records into the existing Department of Homeland Security-wide system of records notice titled, Department of Homeland Security/ALL—003 General Training Records System of Records.

DATES: These changes will take effect on November 27, 2009.

FOR FURTHER INFORMATION CONTACT: For general questions and privacy issues please contact: Mary Ellen Callahan (703-235-0790), Chief Privacy Officer, Privacy Office, U.S. Department of Homeland Security, Washington, DC 20528.

SUPPLEMENTARY INFORMATION: Pursuant to the provisions of the Privacy Act of 1974, 5 U.S.C. 552a, and as part of its ongoing integration and management efforts, the Department of Homeland Security (DHS) is consolidating the system of records notice titled, DHS/Office of Inspector General (OIG)—001 Audit Training Tracking System of Records (70 FR 20154, April 18, 2005).

DHS will continue to collect and maintain records regarding audit training and will rely upon the existing DHS-wide system of records notice titled, DHS/ALL—003 General Training Records System of Records (73 FR 71656, November 25, 2008).

Eliminating this notice will have no adverse impacts on individuals, but will promote the overall streamlining and management of DHS Privacy Act record systems.